US major Eli Lilly & Co. (NYSE: LLY) announced plans to establish four new pharmaceutical manufacturing sites in the United States. The move aims to boost the company’s domestic medicine production across various therapeutic areas.
API Manufacturing and Supply Chain Strengthening
Three of the new sites will focus on manufacturing active pharmaceutical ingredients (API). This will reshore critical capabilities of small molecule chemical synthesis and further strengthen Lilly’s supply chain. The fourth site will extend the company’s global parenteral manufacturing network for future injectable therapies.
Job Creation and Investment
The establishment of these new sites is expected to create over 3000 jobs for highly skilled workers, including engineers, scientists, operations personnel, and lab technicians. Previously, Lilly committed a total of USD 23 billion to domestic capital expansion from 2020 to 2024. The new pledge represents an additional USD 27 billion in planned spending, bringing the total outlay to over USD 50 billion.
Company Statement and Site Details
“This represents the largest pharmaceutical expansion investment in US history,” said Lilly CEO David Ricks. The new sites will be located in Research Triangle Park and Concord, North Carolina, as well as the LEAP Innovation District in Lebanon, Indiana. There will also be expansions and updates to several manufacturing facilities in Indianapolis, the development of the new Lilly Medicine Foundry in Lebanon, Indiana, and the acquisition and expansion of Lilly’s manufacturing site in Kenosha County, Wisconsin.-Fineline Info & Tech
Leave a Reply